It is not intuitively obvious why a treatment should work for chronic multiple sclerosis, but not for acute therapy. But that is what Elan Corp. plc hopes will be the case, after the company announced last week that its Antegren (natalizumaba) anti-a4 integrin antibody failed to show efficacy in a Phase II acute therapy trial. The company now will only pursue chronic treatment of MS after the